CB1 antagonists such as AVE1625 are potentially useful in the treatment of obesity, smoking cessation and cognitive impairment. Proof of pharmacological action of AVE1625 in the brain can be given by antagonising the effects of delta-9-tetrahydrocannabinol (THC), a CB1/CB2 agonist. Inhibition of THC-induced effects by AVE1625 was observed on Visual Analogue Scales ‘alertness’, ‘feeling high’, ‘external perception’, ‘body sway’ and ‘heart rate’. Even the lowest dose of AVE1625 20 mg inhibited most of THC-induced effects. AVE1625 did not have any effect on psychological and behavioural parameters or heart rate by itself. After THC and AVE1625 administration, changes on electroencephalography were observed. This study shows a useful method for studying the effects of CB1 antagonists. AVE1625 penetrates the brain and antagonises THC-induced effects with doses at or above 20 mg.
Benarroch, E. ( 2007) Endocannabinoids in basal ganglia circuits: implications for Parkinson disease. Neurology69: 306-309.
2.
Bond, A., Lader, M. ( 1974) The use of analogue scales in rating subjective feelings . Br J Med Psychol47: 211-218.
3.
Bowdle, TA, Radant, AD, Cowley, DS, Kharasch, ED, Strassman, RJ, Roy-Byrne, PP ( 1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology88: 82-88.
4.
Burns, HD, Van Laere, K., Sanabria-Bohorquez, S., Hamill, TG, Bormans, G., Eng, WS, et al. (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor . Proc Natl Acad Sci U S A104: 9800-9805.
5.
Cahill, K., Ussher, M. ( 2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev: CD005353.
6.
Casswell, S. ( 1975) Cannabis intoxication: effects of monetary incentive on performance, a controlled investigation of behavioural tolerance in moderate users of cannabis. Percept Mot Skills41: 423-434.
7.
Choi, YH, Hazekamp, A., Peltenburg-Looman, AM, Frederich, M., Erkelens, C., Lefeber, AW, et al. (2004) NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa. Phytochem Anal15: 345-354.
8.
Cooper, SJ ( 2004) Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. Eur J Pharmacol500: 37-49.
9.
DSouza, DC, Abi-Saab, WM, Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry57: 594-608.
10.
DSouza, DC, Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, YT, et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis . Neuropsychopharmacology29: 1558-1572.
11.
Di Forti, M., Morrison, PD, Butt, A., Murray, RM ( 2007) Cannabis use and psychiatric and cogitive disorders: the chicken or the egg. Curr Opin Psychiatry20: 228-234.
12.
Elsohly, MA, Slade, D. ( 2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci78: 539-548.
13.
Fernandez-Espejo, E., Caraballo, I., de Fonseca, FR, El Banoua, F., Ferrer, B., Flores, JA, et al. (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism . Neurobiol Dis18: 591-601.
14.
Hazekamp, A., Peltenburg, A., Verpoorte, R., Giroud, C. ( 2005) Chromatographic and spectroscopic data of cannabinoids from Cannabis sativa L. J Liq Chromatogr Relat Technol28: 2361-2382.
15.
Hazekamp, A., Ruhaak, R., Zuurman, L., van Gerven, J., Verpoorte, R. ( 2006) Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci95: 1308-1317.
16.
Hazekamp, A., Simons, R., Peltenburg-Looman, AMG, Sengers, M., van Zweden, R., Verpoorte, R. ( 2004) Preparative isolation of cannabinoids from cannabis sativa by centrifugal partitioning chromatography. J Liq Chromatogr Relat Technol27: 2421-2440.
17.
Huestis, MA, Boyd, SJ, Heishman, SJ, Preston, KL, Bonnet, D., Le Fur, G., et al. (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl)194: 505-515.
18.
Huestis, MA, Gorelick, DA, Heishman, SJ, Preston, KL, Nelson, RA, Moolchan, ET, et al. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry58: 322-328.
19.
Meltzer, HY, Arvanitis, L., Bauer, D., Rein, W. ( 2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry161: 975-984.
20.
Mesnage, V., Houeto, JL, Bonnet, AM, Clavier, I., Arnulf, I., Cattelin, F., et al. (2004) Neurokinin, B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol27: 108-110.
21.
Naef, M., Russmann, S., Petersen-Felix, S., Brenneisen, R. ( 2004) Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci93: 1176-1184.
22.
Norris, H. ( 1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology10: 181-191.
23.
Pertwee, RG ( 1999) Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci65: 597-605.
24.
Strougo, A., Zuurman, L., Roy, C., Pinquier, JL, Cohen, AFGerven, JMAv, et al. Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids (accepted August 2007 by Journal of Psychopharmacology).
25.
Van Gaal, LF, Rissanen, A., Scheen, AJ, Ziegler, O., Rossner, S. ( 2005a) Effect of rimonabant on weight reduction and cardiovascular risk - Authors’ reply. Lancet366: 369-370.
26.
Van Gaal, LF, Rissanen, AM, Scheen, AJ, Ziegler, O., Rossner, S. ( 2005b) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet365: 1389-1397.
Zavitsanou, K., Garrick, T., Huang, XF ( 2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia . Prog Neuropsychopharmacol Biol Psychiatry28: 355-360.
29.
Zuurman, L., Roy, C., Schoemaker, R., Hazekamp, A.Hartigh, Jd, Bender, J., et al. (2008) Effect of intrapulmonary THC administration in humans (accepted August 2007 by Journal of Psychopharmacology).
